paper data s1 source data experimental models (SAS institute)
96
Structured Review
SAS institute
paper data s1 source data experimental models
Paper Data S1 Source Data Experimental Models, supplied by SAS institute, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/paper+data+s1+source+data+experimental+models/SAS%2FIML/pm41270737-817-25-57
Average 96 stars, based on 1 article reviews
Paper Data S1 Source Data Experimental Models, supplied by SAS institute, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/paper+data+s1+source+data+experimental+models/SAS%2FIML/pm41270737-817-25-57
Average 96 stars, based on 1 article reviews
paper data s1 source data experimental models - by Bioz Stars,
2026-11
96/100 stars
Images
Related Articles
Quantitative RT-PCR:Article Title: Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD. Article Snippet: In brief Long et al. identified heterogeneity in the efficacy of resistant starch (RS) for treating MASLD.. Baseline multi-omics analysis pinpoints gut microbiota, particularly Prevotella and Bifidobacterium pseudocatenulatum, as the key mediator through influencing RS utilization.. These findings, together with a response prediction model, can promote microbiome-directed precision medicine for MASLD. Software:Article Title: Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD. Article Snippet: In brief Long et al. identified heterogeneity in the efficacy of resistant starch (RS) for treating MASLD.. Baseline multi-omics analysis pinpoints gut microbiota, particularly Prevotella and Bifidobacterium pseudocatenulatum, as the key mediator through influencing RS utilization.. These findings, together with a response prediction model, can promote microbiome-directed precision medicine for MASLD. Starch:Article Title: Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD. Article Snippet: In brief Long et al. identified heterogeneity in the efficacy of resistant starch (RS) for treating MASLD.. Baseline multi-omics analysis pinpoints gut microbiota, particularly Prevotella and Bifidobacterium pseudocatenulatum, as the key mediator through influencing RS utilization.. These findings, together with a response prediction model, can promote microbiome-directed precision medicine for MASLD. Imaging:Article Title: Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD. Article Snippet: In brief Long et al. identified heterogeneity in the efficacy of resistant starch (RS) for treating MASLD.. Baseline multi-omics analysis pinpoints gut microbiota, particularly Prevotella and Bifidobacterium pseudocatenulatum, as the key mediator through influencing RS utilization.. These findings, together with a response prediction model, can promote microbiome-directed precision medicine for MASLD. Spectrophotometry:Article Title: Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD. Article Snippet: In brief Long et al. identified heterogeneity in the efficacy of resistant starch (RS) for treating MASLD.. Baseline multi-omics analysis pinpoints gut microbiota, particularly Prevotella and Bifidobacterium pseudocatenulatum, as the key mediator through influencing RS utilization.. These findings, together with a response prediction model, can promote microbiome-directed precision medicine for MASLD. Real-time Polymerase Chain Reaction:Article Title: Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD. Article Snippet: In brief Long et al. identified heterogeneity in the efficacy of resistant starch (RS) for treating MASLD.. Baseline multi-omics analysis pinpoints gut microbiota, particularly Prevotella and Bifidobacterium pseudocatenulatum, as the key mediator through influencing RS utilization.. These findings, together with a response prediction model, can promote microbiome-directed precision medicine for MASLD. |